Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

GTI1201

Efficacy and safety of alpha1-proteinase inhibitor (human), modified process (alpha-1 mp) in subjects with pulmonary emphysema due to alpha1 antitrypsin deficiency (aatd)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT01983241
Pulmonary Emphysema
Alpha-1 Antitrypsin Deficiency
AATD
Alpha-1 PI Deficiency
Alpha-1 Proteinase Inhibitor
Source :Importé depuis le centre
Pulmonary Emphysema in Alpha-1 PI Deficiency
Recrutement fermé
Dernière modification : 2026/03/03
Type de recherche

Interventionnel

Médicament expérimental

PHASE3


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Pulmonary Emphysema in Alpha-1 PI Deficiency

Source : Importé depuis le centre

Profil des participants

Limites d'âge
minimum : 18 ans maximum : 70 ans
Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Have a documented total alpha1-PI serum level \< 11 µM.
* Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles.
* At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and \< 80% of predicted and FEV1/forced vital capacity (FVC) \< 70% (Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] stage II or III).
* Have a carbon monoxide diffusing capacity (DLCO) ≤ 60% of predicted (corrected for HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the past 2 years per the Investigator's judgment.
* Have clinical evidence of pulmonary emphysema per the Investigator's judgment.

Exclusion Criteria:

* Has received alpha1-PI augmentation therapy for more than 1 month within the six months prior to the Screening Visit.
* Has received alpha1-PI augmentation therapy within one month of the Screening Visit.
* Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
* Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g., claustrophobic) undergo a CT scan.
* History of lung or liver transplant.
* Any lung surgery during the past 2 years (excluding lung biopsy).
* On the waiting list for lung surgery, including lung transplant.
* Smoking during the past 12 months or a positive urine cotinine test at screening that is due to smoking. Maybe on Nicotine replacement, including vapor cigarettes.
* History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
* Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids are not considered systemic steroids) or during the Screening Phase.
* Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
* Known selective or severe Immunoglobulin A (IgA) deficiency.

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Alpha-1 MP 60 mg/kg Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks Donnée non disponible
  • Inconnu
  • Alpha-1 MP 120 mg/kg Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks Donnée non disponible
  • Inconnu
  • Placebo 0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks Donnée non disponible
  • Inconnu
  • Alpha-1 MP 60 mg/kg
    État du recrutement
    unknown
    Alpha-1 MP 120 mg/kg
    État du recrutement
    unknown
    Placebo
    État du recrutement
    unknown
    Données à jour depuis : 3 mars 2026

    Description de l'étude

    Résumé de l'étude

    This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.

    Source : Importé depuis le centre

    Sites

    Centres participants

      10 affichés sur 38 centres
    • GRIFOLS INVESTIGATIVE SITE

      Vicente lópez

      BUENOS AIRES, ARGENTINA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Córdoba

      CÓRDOBA PROVINCE, ARGENTINA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Fortitude valley

      QUEENSLAND, AUSTRALIA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Santo andré

      SÃO PAULO, BRAZIL

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      São paulo

      SÃO PAULO, BRAZIL

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      St. john's

      NEWFOUNDLAND AND LABRADOR, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Halifax

      NOVA SCOTIA, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Toronto

      ONTARIO, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Arhus c

      DENMARK

      Recrutement local
      État du recrutement: FERMÉ
    • GRIFOLS INVESTIGATIVE SITE

      Chandler

      ARIZONA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 3 mars 2026
    Données à jour depuis : 5 mars
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT01983241